Literature DB >> 15006609

HSV-1 virions engineered for specific binding to cell surface receptors.

Paola Grandi1, Samuel Wang, Deborah Schuback, Victor Krasnykh, Matthew Spear, David T Curiel, Roberto Manservigi, Xandra O Breakefield.   

Abstract

Expression of specific peptide epitopes on the surface of virions has significant potential for studying viral biology and designing vectors for targeted gene therapy. In this study, an HSV-1 amplicon plasmid expressing a modified glycoprotein C (gC), in which the heparan sulfate binding domain was replaced with a His-tag, was used in generating HSV-1 virions. Western blot analysis demonstrated the presence of modified gC in the purified virions. The amplicon vectors were packaged using a gC-, lacZ+ helper virus to generate a mixture of high-titer helper virus (lacZ+) and amplicon vectors (GFP+), which expressed modified gC in the virion envelope. His-tagged virions bound to 293 6H cells expressing a cell surface pseudo-His-tag receptor four-fold more efficiently than to parental 293 cells and also proved more effective than wild-type virus in binding to both cell types. Binding resulted in productive infection by the modified virions with expression of reporter genes and cytopathic effect comparable to those of wild-type virions. Thus, not only can HSV-1 tropism be manipulated to recognize a non-herpes simplex binding receptor, but it is also possible to increase the infective capacity of the vectors beyond that of the wild-type virus via specific ligand receptor combinations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006609     DOI: 10.1016/j.ymthe.2003.12.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  13 in total

1.  Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein.

Authors:  Xiaodan Wang; Lingxin Kong; Guo-rong Zhang; Mei Sun; Alfred I Geller
Journal:  Brain Res Mol Brain Res       Date:  2005-09-13

Review 2.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Authors:  Christian Goetz; Matthias Gromeier
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-17       Impact factor: 7.638

3.  Antibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits.

Authors:  Haiyan Cao; Guo-rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2011-08-11       Impact factor: 3.252

Review 4.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

5.  Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A protein.

Authors:  Haiyan Cao; Guo-Rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2010-06-28       Impact factor: 3.252

6.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

Review 7.  HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain.

Authors:  J R Goss; M S Gold; J C Glorioso
Journal:  Gene Ther       Date:  2009-04       Impact factor: 5.250

Review 8.  Retargeting of herpes simplex virus (HSV) vectors.

Authors:  William F Goins; Bonnie Hall; Justus B Cohen; Joseph C Glorioso
Journal:  Curr Opin Virol       Date:  2016-09-08       Impact factor: 7.090

9.  Herpes Virus Amplicon Vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

10.  Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.

Authors:  A W Hudacek; C K Navaratnarajah; R Cattaneo
Journal:  Cancer Gene Ther       Date:  2013-01-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.